PubMed Trending Research Digest — June 19, 2026
A curated digest of 97 trending PubMed articles, automatically categorised and summarised across 15 research areas.
Jump to category
PubMed Trending Research Digest — June 19, 2026
Automated digest · 97 articles · 15 research areas · June 19, 2026
Overview
Across this week’s papers, a dominant theme is precision medicine enabled by better biomarkers, better measurement, and more mechanistic targeting. In oncology, several studies focus on improving how response and risk are assessed—using AI/omics and dynamic sampling (e.g., circulating tumor cell expression tracking during antibody-drug conjugate therapy), and advancing imaging endpoints (AI-based volumetric response for mesothelioma). Complementing this, multiple mechanistic cancer studies identify vulnerabilities tied to therapy-induced states (such as persister formation and resistance programs in EGFR-mutant NSCLC) and map how tumor microenvironments (fibroblast niches and tertiary lymphoid structures) shape immune access and efficacy.
A second major theme is immune modulation—both in infectious disease and in chronic inflammatory/autoimmune conditions. New strategies include mucosal coronavirus vaccination platforms designed to localize immune activation with reduced systemic exposure, and evidence strengthening causal links between exposures (e.g., daily cannabis use) and neuropsychiatric outcomes. In autoimmune disease, trials and translational work continue to refine biologic selection and monitoring (e.g., proteomic or functional antibody readouts to predict response; comparative analyses of biologic durability under real-world adherence). Several studies also emphasize operational translation—how to deliver complex therapies safely in practice.
Finally, many articles converge on cellular and systems mechanisms underlying disease and aging, often pointing to actionable targets. Examples include RNA quality-control pathways for nuclear export/degradation, replication initiation choreography, mitochondrial dysfunction as a recurring driver across contexts (cardiomyopathy, osteoarthritis, neurodegeneration, and ferroptosis/metabolic control), and developmental timing windows in neurodevelopmental disorders and fertility. Together, these studies illustrate a broad shift toward combining high-resolution molecular atlases and mechanistic experiments with clinical trial design and real-world implementation to accelerate durable, targeted interventions.
Prenatal & Early-Life Environmental Exposures
Weight-loss dynamics with tirzepatide versus semaglutide.
This retrospective EHR-based cohort study compared weight-loss dynamics over 2 years between tirzepatide and semaglutide in 1:1 propensity-matched patients (n=10,339 per group) with obesity and/or type 2 diabetes. Patients were stratified into five response groups based on maximum weight loss, and adverse events were identified via AI-enabled curation of clinical notes. The findings aim to clarify variability in GLP-1–based treatment response and support more personalized expectations for weight-loss trajectories with tirzepatide versus semaglutide.
Venkatakrishnan AJ, Murugadoss K, Soundararajan V · PNAS nexus · (2026) · View on PubMed ↗
Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bacteremia.
This study compared cefazolin versus an antistaphylococcal penicillin (flucloxacillin or cloxacillin) in adult patients with penicillin-resistant, methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia in an international Bayesian adaptive platform trial. Cefazolin was evaluated against the primary endpoint of all-cause death within 90 days using a hierarchical Bayesian logistic-regression model. The trial is scientifically and clinically important because it aims to establish the optimal first-line beta-lactam choice for MSSA bacteremia to reduce mortality.
Lee TC, Barina LA, Walls G et al. · The New England journal of medicine · (2026) · View on PubMed ↗
Gestational Exposure to 10 Classes of Priority Chemicals and Birth Outcomes in the ECHO Cohort.
This study evaluated associations between gestational urinary exposure to 10 classes of priority environmental chemicals and birth outcomes in 5318 mother–child pairs from the prospective ECHO cohort in the US. Gestational exposure levels to specific chemical classes were associated with differences in gestational age at birth and/or birth weight. These findings support the need to better characterize and potentially mitigate prenatal exposure to understudied chemical classes to improve perinatal health.
Buckley JP, Pacyga DC, Xun X et al. · JAMA network open · (2026) · View on PubMed ↗ · Free PDF ↗
Cancer Immunotherapy & Biologics (Clinical Trials/Comparative)
CD4+ T cells impair tumor growth through IL-3 and TNF-dependent vascular damage.
The study analyzed how tumor antigen-specific CD4+ T cells affect tumor growth through IL-3 and TNF-dependent vascular damage, using multiplex immunofluorescence and single-cell/tissue transcriptomics to define tumor stroma interactions. CD4+ T cells induced perivascular clusters of classically activated macrophages that produced TNF in response to T cell-derived IL-3, and TNF-mediated vascular injury impaired tumor growth. This reveals an indirect, stroma-targeting mechanism by which CD4+ T cells can drive therapeutic anti-tumor effects, highlighting IL-3/TNF–vascular pathways as potential targets to enhance immunotherapy.
Lian Q, Nie J, Singh J et al. · Science (New York, N.Y.) · (2026) · View on PubMed ↗
Second Primary Malignant Neoplasms After T-Cell-Engaging Bispecific Antibody Therapy: A Systematic Review and Meta-Analysis.
This systematic review and meta-analysis evaluated the frequency of second primary malignant neoplasms (SPMs) reported after treatment with T-cell–engaging bispecific antibodies in patients with B-cell non-Hodgkin lymphoma and multiple myeloma. The analysis aimed to determine how study-level characteristics and reporting definitions influence estimated SPM rates, addressing limitations from small single-arm trials and short follow-up. Clinically, quantifying SPM risk is important for long-term safety monitoring and for interpreting benefit–risk tradeoffs as T-cell–engaging BsAbs move to earlier lines of therapy.
Tomasik J, Tix T, Alhomoud M et al. · JAMA oncology · (2026) · View on PubMed ↗
Teclistamab in relapsed/refractory light chain amyloidosis: A retrospective multicenter study by the German Society for Amyloid Diseases.
This retrospective multicenter German study evaluated teclistamab, an anti-CD3 T-cell engager, in 52 patients with relapsed/refractory systemic AL (light chain) amyloidosis. The key finding was high hematologic response with ≥very good partial response (VGPR) in 81% by Day 15 and 95% by 3 months, indicating strong efficacy and acceptable tolerability in this setting. This is significant because it provides real-world evidence for a previously unapproved option in relapsed/refractory AL amyloidosis and supports further prospective evaluation.
Carpinteiro A, Kimmich C, Trajanova D et al. · HemaSphere · (2026) · View on PubMed ↗
Cancer-associated fibroblasts and tertiary lymphoid structure orchestrate the spatial architecture of tumor immunity.
This mechanistic cancer immunology study examined how cancer-associated fibroblasts (CAFs) and tertiary lymphoid structures (TLS) organize the spatial architecture of tumor immunity. The key finding is that CAFs and TLS act as complementary spatial regulators—CAFs can remodel extracellular matrix, limit lymphocyte infiltration, and promote resistance, while certain CAF subsets can support antigen presentation and TLS organization. This is significant because it identifies spatial niche components that could be targeted to improve anti-tumor immune responses and therapeutic outcomes.
Tang H, Shi Y, Ge Q et al. · Journal of hematology & oncology · (2026) · View on PubMed ↗
Antibody-drug conjugates in gynaecological cancers: opportunities and challenges.
This narrative review assessed the clinical landscape of antibody-drug conjugates (ADCs) in gynecological cancers, including approved agents and ongoing research directions. It highlights that mirvetuximab soravtansine (FRα+ ovarian cancer), trastuzumab deruxtecan (HER2 IHC 3+ solid tumors), and tisotumab vedotin (cervical cancer) are established options, while major challenges include resistance mechanisms and optimal sequencing. The significance lies in consolidating current evidence and prioritizing actionable research needs to expand ADC effectiveness in gynecologic malignancies.
Moore KN, Yeku OO, Howitt BE et al. · Nature reviews. Clinical oncology · (2026) · View on PubMed ↗
Prognostic value of systemic inflammatory markers in avelumab maintenance for advanced urothelial carcinoma: the multicentric SAILOR analysis.
This multicentric retrospective SAILOR analysis studied systemic inflammatory markers (NLR, NER, LMR, PLR and related composite indices) in patients with advanced urothelial carcinoma receiving avelumab maintenance. Higher-risk inflammatory profiles were associated with worse outcomes and the authors developed a composite inflammatory score to stratify prognosis. These findings support using readily available blood-based inflammation metrics to refine risk prediction during avelumab maintenance in advanced urothelial cancer.
Maiorano BA, Roviello G, Rizzo A et al. · Scientific reports · (2026) · View on PubMed ↗
Tremelimumab with or without durvalumab in combination with paclitaxel in metastatic urothelial cancer: phase I/II ICRA trial.
In the phase I/II ICRA trial, metastatic urothelial cancer patients after platinum chemotherapy and immune checkpoint inhibition were randomized to paclitaxel plus tremelimumab (T) with or without durvalumab (D) or to tremelimumab alone. The study reported objective response rates of 26% in arm A (paclitaxel + T750), 17% in arm B (paclitaxel + T300 + D1500), and 8% in arm C (T750), meeting the primary response endpoint in arm A. These results provide early clinical evidence for combining tremelimumab with paclitaxel (and potentially durvalumab) as a post-ICI strategy in therapy-refractory metastatic urothelial cancer.
Einerhand SMH, Ali H, Wong SQ et al. · Nature communications · (2026) · View on PubMed ↗
Becotatug Vedotin for Recurrent/Metastatic Nasopharyngeal Carcinoma (Magic-M001): A Multicenter, Randomized Trial.
This multicenter randomized trial studied becotatug vedotin, an anti–epidermal growth factor receptor antibody-drug conjugate, in adults with recurrent/metastatic nasopharyngeal carcinoma (NPC) after failure of at least two systemic lines including PD-1/PD-L1 inhibitors and chemotherapy. The key finding was the trial’s comparative efficacy and safety of becotatug vedotin versus standard chemotherapy (capecitabine or docetaxel) as assessed by co-primary endpoints. If positive, this would support becotatug vedotin as a new post–PD-1/PD-L1 treatment option for recurrent/metastatic NPC.
Han F, Xiang YQ, Wang XH et al. · Annals of oncology : official journal of the European Society for Medical Oncology · (2026) · View on PubMed ↗
Practical Management of Bispecific Antibodies in Multiple Myeloma.
This JCO Oncology Practice review summarizes practical delivery considerations for T-cell–redirecting bispecific antibodies in relapsed/refractory multiple myeloma, focusing on agents targeting B-cell maturation antigen (teclistamab, elranatamab, linvoseltamab) and GPRC5D (talquetamab). It highlights operational and clinical challenges when transitioning these off-the-shelf therapies from trials to routine academic and community practice, including patient selection and safe administration workflows. The review is clinically significant because it provides a framework to improve real-world safety and effectiveness of bispecific antibody therapy.
Tan CR, Korde N, Mian H · JCO oncology practice · (2026) · View on PubMed ↗
Plasma proteomics improves thrombosis prediction in patients with cancer and identifies targetable IL-17-driven endothelial activation.
This prospective study used high-throughput plasma proteomics to improve venous thromboembolism (VTE) prediction in patients with newly diagnosed lung or gastric cancer, monitored for VTE development. A Bayesian probabilistic machine-learning model incorporating 11 protein biomarkers plus five clinical parameters (age, sex, history of VTE, body mass index, hemoglobin) outperformed standard risk models and implicated IL-17–driven endothelial activation as a targetable mechanism. The results are clinically significant because they both enhance VTE risk stratification and identify a potential therapeutic target in cancer-associated thrombosis.
Karagkouni D, Brake MA, Patell R et al. · Science translational medicine · (2026) · View on PubMed ↗
WT1 peptide vaccines of post-allogeneic HSCT maintenance immunotherapy for pediatric acute leukemias: a phase II study.
This phase II clinical trial studied WT1 peptide vaccines (MCI-for) as post-allogeneic HSCT maintenance immunotherapy in 17 pediatric patients with refractory acute leukemias. The primary endpoint, 3-year overall survival, was 70.6% (95% CI 43.1–86.6%), exceeding a 30% historical control benchmark, with benefit associated with patients who achieved complete remission by year 1 after vaccination. These results support WT1 peptide maintenance as a potentially effective immunotherapy strategy after allo-HSCT in children with acute leukemia.
Hashii Y, Oka Y, Sakata N et al. · Blood advances · (2026) · View on PubMed ↗
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial.
This randomized, double-blind, placebo-controlled phase 3 trial assessed whether adding ivonescimab (a bispecific antibody targeting PD-1 and VEGF) to chemotherapy improves overall survival in patients with EGFR-variant nonsquamous NSCLC who progressed after prior EGFR TKI therapy. The key result was that ivonescimab plus chemotherapy improved overall survival compared with placebo plus chemotherapy in this post–EGFR TKI population. Clinically, this provides evidence for a new targeted immuno-angiogenic strategy to extend survival after EGFR TKI failure in EGFR-mutant/non–small cell lung cancer.
Fang W, Zhao Y, Luo Y et al. · JAMA · (2026) · View on PubMed ↗
Cancer Targeted Therapy & Resistance Mechanisms
Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer.
The study examined how TROP2 regulates drug-tolerant persister (DTP) cell formation and EGFR TKI resistance in EGFR-mutant non-small-cell lung cancer, focusing on the c-Myc–MAPK signaling axis and testing therapies in preclinical models. TKI-induced MAPK inhibition lowered c-Myc, which dynamically upregulated TROP2 to maintain DTPs, and combining the TROP2-targeting antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) with osimertinib suppressed DTP emergence and delayed tumor relapse. This supports TROP2 as a mechanistic vulnerability to prevent or delay osimertinib resistance in EGFR-mutant NSCLC by targeting the persister state rather than only bulk tumor cells.
Liao J, Yao W, Yu Y et al. · Cancer cell · (2026) · View on PubMed ↗
Induced pluripotent stem cell-derived models of malignant nerve sheath tumor progression mimic glial to neuro-mesenchymal transition and uncover therapeutic opportunities.
Using gene-edited iPSC-derived neural crest models, this study investigated malignant peripheral nerve sheath tumor progression relevant to neurofibromatosis type 1 by sequentially knocking out NF1 and CDKN2A and then PRC2 components. NF1-CDKN2A double knockout produced neurofibroma-like tumors in vivo, while additional PRC2 loss drove mesenchymal stem cell-like features and disrupted pluripotency, recapitulating glial-to-neuro-mesenchymal transition-like changes. The iPSC model identifies mechanistic gene dependencies (NF1, CDKN2A, PRC2) that can be leveraged to discover targeted therapies for MPNST.
Uriarte-Arrazola I, Magallón-Lorenz M, Fernández-Rodríguez J et al. · Nature communications · (2026) · View on PubMed ↗
IDH1-R132H enhances oncolytic HSV-1 therapy by facilitating viral entry and immune activation in glioma.
This study evaluated an engineered oncolytic herpes simplex virus-1, rQNestin34.5v.2 (CAN-3110), in IDH1-R132H-mutant diffuse gliomas to determine how the IDH1 mutation affects viral entry and immune activation. IDH1-R132H increased susceptibility to infection by upregulating Nectin-1 (the HSV-1 entry receptor), and the mutation-driven DNA hypermethylation altered downstream immune-related responses. The work supports precision virotherapy by using IDH1-R132H status to enhance oncolytic HSV-1 efficacy and immunostimulatory activity in glioma.
Panagioti E, Kelley HJ, Ling AL et al. · Nature communications · (2026) · View on PubMed ↗
Oncology Diagnostics & Imaging Biomarkers
Single-Fraction Stereotactic Body Radiotherapy for Localized Prostate Cancer: A Nonrandomized Clinical Trial.
The study assessed whether single-fraction stereotactic body radiotherapy (SBRT) is effective and safe for men with low- or intermediate-risk localized prostate cancer in a multicenter, single-arm, prospective phase 1/2 nonrandomized clinical trial. The trial evaluated biochemical disease control and treatment-related safety as a potential alternative to the standard 5-fraction SBRT approach. If effective, single-fraction SBRT could simplify treatment delivery and reduce patient burden while maintaining oncologic outcomes.
Zilli T, Franzese C, Guckenberger M et al. · JAMA oncology · (2026) · View on PubMed ↗
AI-derived bone mineral density from standard radiographs compared with DXA for fracture prediction in a 10-year real-world cohort study.
This real-world cohort study compared AI-derived bone mineral density (BMD) extracted from standard radiographs with DXA measurements and assessed fracture prediction over 10 years. AI-derived BMD agreed strongly with DXA and showed comparable ability to predict incident fractures, supporting an opportunistic screening approach without dedicated DXA. Scientifically and clinically, this could expand osteoporosis risk detection using existing imaging workflows, potentially enabling earlier intervention for fracture prevention.
Tseng TH, Huang TT, Huang JE et al. · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · (2026) · View on PubMed ↗
Development and validation of artificial intelligence-assisted volumetric response criteria in pleural mesothelioma (ARTIMES): a retrospective, multicohort, multicentre study.
The ARTIMES study developed and validated AI-assisted volumetric response criteria for pleural mesothelioma using automated tumour segmentation and biologically derived thresholds. Using 10,926 CT scans from 2080 patients across 14 cohorts (with annotated subsets from routine care and multiple trials), it found that volumetric AI criteria improved response assessment for the crescent-shaped tumour growth pattern compared with diameter-based approaches. This is scientifically and clinically significant because it can standardize and potentially improve imaging endpoints in mesothelioma trials and practice.
Lipman KBWG, Wittenberg R, de Oliveira Taveira M et al. · The Lancet. Oncology · (2026) · View on PubMed ↗
Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma.
This study evaluated high-throughput Hi-C DNA sequencing on FFPE tissues from 159 patients with diffuse large B-cell lymphoma (DLBCL) to detect oncogene rearrangements for diagnosis and treatment planning. Hi-C sequencing identified 746 cancer genes at or proximal to rearrangement breakpoints across 1903 occurrences, demonstrating genome-wide rearrangement detection in a single assay. Clinically, this could complement or reduce reliance on FISH by providing broader rearrangement profiling to guide lymphoma management.
Xu-Monette ZY, Wang C, Wu D et al. · Blood advances · (2026) · View on PubMed ↗
Dynamic monitoring of antibody drug conjugates targeting TROP2 or HER2 in breast cancer using circulating tumor cells.
This study used serial quantitative imaging of circulating tumor cells (CTCs) in a prospective cohort of 35 patients to monitor antibody drug conjugates targeting TROP2 (sacituzumab govitecan) or HER2 (T-DXd) in metastatic breast cancer. It found that single-cell expression dynamics of TROP2 and HER2 on CTCs could be tracked during treatment, addressing the mismatch between bulk biopsy epitope levels and clinical response. The approach provides a noninvasive, dynamic biomarker strategy to better understand and potentially predict ADC response.
Mishra A, Abelman RO, Cunneely Q et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗
Cardiovascular Disease (Clinical Trials/Guidelines/Outcomes)
Strategies for Optimizing Heart Failure Care in the Older Adult: A Scientific Statement From the American Heart Association.
This American Heart Association scientific statement reviewed evidence and proposed strategies to optimize heart failure care specifically for older adults (≥65 years), focusing on barriers to guideline-directed, disease-modifying therapies. It emphasized tailoring treatment plans to improve access, navigation, and implementation of therapies among patients at highest risk of cardiovascular death or worsening heart failure. The significance is practical: it guides clinicians on how to deliver patient-centered, evidence-based care despite age-related and system-level obstacles.
Lewsey SC, Martyn T, Blumer V et al. · Circulation · (2026) · View on PubMed ↗
Laparoscopic management of Mirizzi syndrome type IV: a case report and review of minimal access surgery.
This case report and review studied a 44-year-old woman with Mirizzi syndrome type IV treated using a minimally invasive laparoscopic approach. The key finding was successful laparoscopic management with rapid, complication-free recovery and no biliary stricture on 6-month follow-up. The report is significant because it challenges the traditional need for open surgery and suggests laparoscopic feasibility in carefully selected patients.
Nguyen NBM, Pham TH, Pham TQ et al. · Journal of minimally invasive surgery · (2026) · View on PubMed ↗
Mitochondrial protein OPA3 sustains cardiac function by regulating calcium handling in male mice.
This study examined how mitochondrial protein OPA3 regulates calcium handling and mitochondrial function in male mice, using cardiomyocyte-specific deletion of Opa3. Opa3 loss caused progressive dilated cardiomyopathy with impaired myocardial function, disrupted Ca2+ cycling, and mitochondrial dysfunction, mechanistically linked to OPA3 multimers required for interaction with phospholamban (PLN). These findings identify OPA3–PLN–calcium/mitochondrial coupling as a potential therapeutic axis for heart failure.
Geng N, Chen T, Li H et al. · Nature communications · (2026) · View on PubMed ↗
Safety and efficacy of staged, bilateral magnetic resonance-guided focused ultrasound pallidothalamic tractotomy for motor complications of Parkinson’s disease: a prospective, multicentre, single-arm trial.
This prospective, multicentre, single-arm trial evaluated staged, bilateral magnetic resonance-guided focused ultrasound (MRgFUS) pallidothalamic tractotomy for motor complications in adults with idiopathic, levodopa-responsive Parkinson’s disease. The key finding was the observed safety profile and efficacy signals for improving motor complications after MRgFUS tractotomy. Clinically, it supports MRgFUS as a less invasive alternative to deep brain stimulation for selected Parkinson’s patients.
Dalvi A, Eisenberg HM, Wu P et al. · The Lancet. Neurology · (2026) · View on PubMed ↗
Safety and efficacy of decompressive craniectomy versus standard craniotomy for large acute epidural haematoma with tentorial herniation in China (PREDICT-AEDH): a nationwide, multicentre, open-label, parallel-group, randomised controlled trial.
The PREDICT-AEDH trial studied decompressive craniectomy versus standard craniotomy in adults (18–65 years) with large acute epidural haematoma complicated by tentorial herniation across 28 hospitals in China. The key finding was the comparative effect on functional outcomes and safety endpoints between the two surgical strategies. If decompressive craniectomy improved outcomes without unacceptable harm, it would directly inform surgical management guidelines for this high-mortality brain injury subgroup.
Feng J, Yang C, Xie L et al. · The Lancet. Neurology · (2026) · View on PubMed ↗
Left Atrial Appendage Closure vs Direct Oral Anticoagulants in Atrial Fibrillation: Meta-Analysis of Randomized Trials.
This updated meta-analysis of randomized trials compared left atrial appendage closure (LAAC) versus direct oral anticoagulants (DOACs) for stroke prevention in atrial fibrillation. The key finding was the pooled assessment of efficacy and bleeding outcomes (stroke, death, and intracranial hemorrhage) using the longest available follow-up from each trial (abstract truncated before the numerical effect estimates). The results help guide comparative decision-making between procedural LAAC and long-term DOAC therapy in AF patients.
Chan YH, Cheng WH, Yeh YH et al. · JACC. Advances · (2026) · View on PubMed ↗
Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical Trial.
This prespecified secondary analysis of the MAPLE-HCM randomized clinical trial compared aficamten versus metoprolol in individuals with obstructive hypertrophic cardiomyopathy (oHCM) using 16 quantitative exercise measures. Aficamten produced a more favorable overall exercise performance profile than metoprolol across stages of exercise. Scientifically and clinically, the results strengthen aficamten’s role as an alternative first-line option to β-blockade for improving functional capacity in oHCM.
Lewis GD, Garcia-Pavia P, Masri A et al. · JAMA cardiology · (2026) · View on PubMed ↗ · Free PDF ↗
Neurodegeneration & Dementia Biomarkers
Affective and cognitive theory of mind and associated brain functional alterations in frontotemporal dementia.
This resting-state fMRI study assessed theory of mind (cognitive and affective ToM) deficits across 67 frontotemporal dementia (FTD) patients spanning non-fluent variant primary progressive aphasia (nfvPPA) and other FTD variants. It found that ToM impairments are associated with specific functional connectivity alterations rather than being confined to a single FTD subtype. The findings are clinically important because they support ToM as a cross-spectrum neurocognitive marker and help identify neural network targets for diagnosis and prognosis in FTD.
Tripodi C, Canu E, Marangon A et al. · Brain communications · (2026) · View on PubMed ↗
Hippocampal GFAP in aging: Associations with AD and LATE-NC pathologies and cognitive decline in older adults.
This study assessed hippocampal GFAP burden in older adults to test associations with Alzheimer’s disease (AD) and AD-related dementias (ADRD) neuropathology, including LATE-NC and cognitive decline. Hippocampal GFAP was associated with specific AD/ADRD pathologies and with measures of cognitive decline after adjusting for demographics and other brain pathologies. These results support hippocampal GFAP as a brain-based biomarker candidate that may track neurodegenerative disease burden and clinical progression.
Agrawal S, Yu L, Leurgans SE et al. · Alzheimer’s & dementia : the journal of the Alzheimer’s Association · (2026) · View on PubMed ↗
Safety and efficacy of levacetylleucine in ataxia-telangiectasia: a phase 3, randomised, double-blind, placebo-controlled crossover trial.
This phase 3, randomised, double-blind, placebo-controlled crossover trial studied levacetylleucine (N-acetyl-L-leucine) in paediatric and adult patients aged ≥4 years with ataxia-telangiectasia across 10 hospitals in Germany, Slovakia, Spain, Switzerland, the UK, and the USA. The trial evaluated levacetylleucine’s safety and efficacy versus placebo, with results reported for neurological outcomes and tolerability (abstract truncated before the primary efficacy/safety effect sizes). If levacetylleucine shows a favorable risk–benefit profile, it would support a disease-modifying therapeutic strategy for neurological manifestations in ATM-related ataxia-telangiectasia.
Martakis K, Bremova-Ertl T, Bolton C et al. · The Lancet. Neurology · (2026) · View on PubMed ↗
Limiting neurodegeneration in ALS: A phosphatase paves the way.
This commentary highlighted preclinical work identifying the phosphatase PGAM5 as a therapeutic target across amyotrophic lateral sclerosis (ALS) subtypes. The key mechanistic finding is that PGAM5 dephosphorylates and activates the stress-regulated mitochondrial peptidase OMA1, driving a maladaptive mitochondrial integrated stress response in motor neurons. Targeting the PGAM5–OMA1 axis could therefore represent a rational disease-modifying approach for ALS.
Rugarli EI, Langer T · Neuron · (2026) · View on PubMed ↗
Clinical Impact and Prognostic Value of Alzheimer Disease Biomarkers in the Very Old.
This retrospective longitudinal cohort study assessed the clinical impact and prognostic value of Alzheimer disease (AD) biomarkers in individuals aged ≥80 years (“very old”) within the Sant Pau Initiative on Neurodegeneration (SPIN) memory clinic cohort in Barcelona, Spain. It evaluated whether AD biomarker status meaningfully improves clinical interpretation and predicts outcomes in this older population. The study is important because it addresses whether AD biomarkers retain utility for diagnosis/prognosis in the very old, where clinical usefulness has been uncertain.
Ceriello C, Torres OH, Rubio-Guerra S et al. · Neurology · (2026) · View on PubMed ↗
Neuroscience (Mechanisms, Brain Circuits, Neuroprosthetics)
Evolutionarily conserved and divergent mechanisms of dual Ca2+ sensors in synaptic vesicle exocytosis.
The study investigated evolutionarily conserved and divergent mechanisms of dual Ca2+ sensors in synaptic vesicle exocytosis at the Caenorhabditis elegans neuromuscular junction, focusing on SNT-1 and SNT-3 and their interactions with the SNARE complex and polybasic motifs. Using AlphaFold 3 modeling of SNT-1/SNARE and SNT-3/SNARE complexes, the authors predicted a C2B–SNARE arrangement consistent with canonical synaptotagmin-1 (Syt1) interfaces while proposing distinct contributions for fast versus slow neurotransmitter release. This advances mechanistic understanding of how dual Ca2+ sensors tune release kinetics across species, informing broader models of synaptic transmission regulation.
Li L, Wang J, Xia J et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗
A mosaic of whole-body representations on the human precentral gyrus.
This study mapped body representations in the human motor cortex at single-neuron resolution using microelectrode array recordings from 20 arrays across 8 individuals with paralysis enrolled in brain-computer interface trials. It found a mosaic organization on the precentral gyrus in which distinct body parts are represented in spatially interleaved patterns rather than a uniform somatotopic map. This improves mechanistic understanding of motor cortical control and can guide more precise decoding strategies for neuroprosthetics.
Deo DR, Okorokova EV, Pritchard AL et al. · Nature · (2026) · View on PubMed ↗
Sex-linked helicases DDX3X and DDX3Y regulate G-quadruplex-associated stress in neurons.
This cellular neuroscience study examined how sex-linked helicases DDX3X and DDX3Y regulate neuronal responses to quarfloxin (CX-3543), a small molecule that stabilizes G-quadruplexes. Quarfloxin induced DNA damage in neurons, with double-strand breaks enriched in the nucleolus, and proteomic analyses showed altered protein networks linked to neurodegenerative diseases. The findings implicate DDX3X/DDX3Y in managing G-quadruplex-associated genotoxic stress, informing how G4-targeting drugs may differentially affect neuronal vulnerability.
Diaz Escarcega R, M J VK, Arizmendez A et al. · Cell death & disease · (2026) · View on PubMed ↗
Atlas of human brain imaging-derived phenotypes and disease risk.
This study leveraged multimodal MRI (T1-weighted, diffusion, and resting-state functional MRI) and linked health records from 64,836 participants to perform a phenome-wide association study (PheWAS) across 505 brain imaging-derived phenotypes (IDPs) and 756 incident diseases spanning 15 organ systems. The key finding was the creation of the largest atlas to date mapping brain structure/function alterations to multisystem disease risk using population-scale neuroimaging associations. Clinically, this atlas can help prioritize neurobiological pathways and improve risk stratification by linking specific imaging phenotypes to future disease outcomes.
Liu Q, Guo J, Yan J et al. · Med (New York, N.Y.) · (2026) · View on PubMed ↗
The translational potential of drug-induced hypothermia in acute ischemic stroke.
This translational study evaluated drug-induced hypothermia as a therapeutic strategy for acute ischemic stroke using chlorpromazine and promethazine (C+P) in mice and in supporting clinical evidence. In mice, C+P induced hypothermia, suppressed brain glucose metabolism, reduced infarct volumes, and improved neurological deficits. The work is significant because it explores a potentially noninvasive, drug-based approach to achieve sustained hypothermic/hypometabolic neuroprotection in ischemic stroke.
Xu S, Wang Q, An H et al. · Science translational medicine · (2026) · View on PubMed ↗
NPAS3-regulated astrocyte mitochondrial bioenergetics is required for cognition.
This study examined the role of NPAS3 in astrocyte mitochondrial bioenergetics and cognition by focusing on NPAS3-regulated metabolic pathways in the mouse brain. Selective deletion of Npas3 in mature astrocytes reduced expression of mitochondrial glutamate carrier 2 (Slc25a22), leading to impaired oxidative phosphorylation and altered lactate production, which was associated with cognitive deficits. The findings are significant because they identify an astrocyte-specific NPAS3–mitochondrial pathway required for cognition, linking transcriptional regulation to behaviorally relevant brain metabolism.
Murlanova K, Novototskaya-Vlasova K, Huseynov S et al. · Science advances · (2026) · View on PubMed ↗
State-switching navigation strategies in Caenorhabditis elegans are beneficial for chemotaxis.
This study investigated how Caenorhabditis elegans switches between steering and turning during chemotaxis and whether internal state contributes to navigation strategy selection. Using measurements of sensory-guided navigation and statistical modeling, it found that state-switching navigation strategies improve chemotaxis performance. The work advances understanding of how behavioral state transitions are implemented to optimize goal-directed movement in response to sensory cues.
Chen KS, Pillow JW, Leifer AM · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗
Gene Therapy & Regenerative Medicine
Targeting lysosomal pH restores mitochondrial quality control in GBA1-mutant Parkinson’s disease.
This translational study used iPSC-derived fibroblasts and dopaminergic neurons from patients with GBA1-mutant Parkinson’s disease (GBA1-PD) to test whether restoring lysosomal pH can correct cellular defects. The key finding was that targeting lysosomal pH improved lysosomal acidification and protease activity and restored mitochondrial quality control, including effects on mitochondrial membrane potential and mitophagy, which are disrupted in GBA1-PD. The work is significant because it links a druggable lysosomal defect (via GBA1-related lysosomal dysfunction) to mitochondrial dysfunction relevant to Parkinson’s disease pathogenesis.
Sheshadri P, Costa-Besada MA, Fisher A et al. · Translational neurodegeneration · (2026) · View on PubMed ↗
Ten years of disease-modifying therapy in spinal muscular atrophy: lessons learned and future directions.
This review summarizes the decade of disease-modifying therapy in spinal muscular atrophy (SMA), a disease caused by loss of SMN1 function, and synthesizes lessons from clinical trials and real-world data. It highlights that three approved therapies have substantially changed the natural history across SMA types, including severe type I, with accumulating evidence supporting safety and efficacy. The clinical significance is guidance for future treatment sequencing, optimization, and research directions as the field moves beyond initial efficacy toward long-term outcomes.
Mercuri E, Finkel RS, Muntoni F · Nature reviews. Neurology · (2026) · View on PubMed ↗
Effects of sevasemten (EDG-5506) on safety, biomarkers, and functional measures in adults with Becker muscular dystrophy: results of a phase 1b, open-label study.
This phase 1b, open-label study evaluated the long-term safety, tolerability, and pharmacokinetics/pharmacodynamics of sevasemten (EDG-5506) in adults with Becker muscular dystrophy (BMD) who had already experienced functional decline. The key finding was the characterization of sevasemten’s safety/tolerability and biomarker/functional effects over longer-term dosing in this BMD population (abstract truncated before the specific outcomes). If favorable, these data support further clinical development of sevasemten as a contraction-modulating therapy aimed at reducing muscle injury in BMD.
Phan H, Barthel B, Madden M et al. · EBioMedicine · (2026) · View on PubMed ↗
AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich Ataxia: A Nonrandomized Clinical Trial.
This nonrandomized clinical trial evaluated safety and preliminary efficacy of AAVrh.10hFXN, an AAVrh.10 serotype vector delivering the normal human FXN coding sequence, in adults with Friedreich ataxia cardiomyopathy caused by pathogenic FXN variants. Administration of AAVrh.10hFXN showed an acceptable safety profile and signals of cardiomyopathy improvement consistent with restored frataxin expression. These findings are significant as early clinical evidence for gene therapy targeting the FXN defect to treat the major cause of death in Friedreich ataxia.
Crystal RG, Weinsaft JW, Kaminsky SM et al. · JAMA cardiology · (2026) · View on PubMed ↗
Infectious Disease (Vaccines, Antimicrobials, Antibody Engineering)
Precision-engineered STING agonist nanoparticles enable coordinated mucosal-systemic immunity for durable pan-β-coronavirus protection.
This study engineered NanoCF501, a precision-engineered STING agonist nanoparticle formulated with a 2-ethyl-2-oxazoline polymer, and tested it as an intranasal mucosal adjuvant in rats and mice. The key finding is that NanoCF501 enables localized respiratory retention with minimal systemic exposure and, when co-administered intranasally with a multivalent pan-β-coronavirus antigen, induces coordinated mucosal and systemic immunity that protects against homologous and heterologous pan-β-coronaviruses. This provides a platform for durable, broad coronavirus vaccination that balances strong mucosal protection with reduced systemic toxicity.
Liu Z, Zhou J, Gao R et al. · Nature nanotechnology · (2026) · View on PubMed ↗
Cervical cancer mortality trends following HPV vaccination in England, 2001-24: an analysis of population-based mortality data.
This population-based analysis studied cervical cancer mortality trends in England from 2001–2024 in relation to the national HPV vaccination programme introduced in 2008 for girls aged 12–13 years with catch-up in 2008–2010. The key finding was an estimated reduction in cervical cancer deaths in young women following HPV vaccination, alongside observed mortality trend changes over time. These results strengthen evidence that HPV vaccination reduces cervical cancer mortality and inform cervical cancer elimination policy.
Sasieni P, Falcaro M · Lancet (London, England) · (2026) · View on PubMed ↗
Benzylpenicillin versus flucloxacillin or cloxacillin for the treatment of penicillin-susceptible Staphylococcus aureus bacteraemia (SNAP): an international, multicentre, open-label, non-inferiority randomised controlled trial.
This international, multicentre, open-label, non-inferiority randomized controlled trial compared benzylpenicillin versus anti-staphylococcal penicillins (flucloxacillin or cloxacillin) for penicillin-susceptible Staphylococcus aureus (PSSA) bacteraemia in adults. The key finding was the trial’s determination of whether benzylpenicillin is non-inferior to anti-staphylococcal penicillins for clinical outcomes while addressing concerns about resistance and tolerability. If non-inferiority was demonstrated, it would support benzylpenicillin as an evidence-based alternative for PSSA bacteraemia treatment.
Lancet (London, England) · (2026) · View on PubMed ↗
Management of Differentiated Thyroid Cancer.
This article reviews risk-adapted management of differentiated thyroid cancer across the clinical pathway from thyroid nodule detection through diagnosis, active surveillance or treatment, and longitudinal follow-up in patients with differentiated thyroid malignancies. It emphasizes that clinicopathologic staging can be dynamically refined with molecular tumor risk characterization to guide and modify therapeutic decisions based on natural history and response to therapy. The framework is clinically significant because it supports more precise, individualized treatment intensity while balancing risks, benefits, and patient preferences over time.
Hegedüs L, Wirth LJ, Tuttle RM · The New England journal of medicine · (2026) · View on PubMed ↗
Engineered antibodies bypass bacterial immune evasion to drive complement-mediated protection against lethal infections.
This study developed engineered antibodies that bypass bacterial immune evasion to drive complement-mediated protection against lethal infections using a targeted complement activation therapy (T-CAT) approach. By furnishing antibodies with enzymatic capability to overcome disruption of the classical pathway initiation complex C1, the engineered antibodies enhanced complement activation and improved survival in lethal infection models. The findings are important because they provide a strategy to make antibody therapies more effective against pathogens that actively block complement.
Ali YM, Yabuki M, Arachchilage CH et al. · Science translational medicine · (2026) · View on PubMed ↗
Deep learning-enabled discovery of antibiotics effective against Neisseria gonorrhoeae.
This study used deep learning to discover antibiotics effective against Neisseria gonorrhoeae by augmenting high-throughput phenotypic screening with a predictive graph neural network (GNN). Researchers phenotypically tested 38,650 small molecules for growth inhibition to train a GNN model that was benchmarked against other architectures, including a large language model, to identify readily available narrow-spectrum candidates. The work is significant because it accelerates antibiotic hit discovery for a highly resistant pathogen by improving the efficiency of screening-to-lead selection.
Anahtar MN, Valeri JA, Modaresi SM et al. · Science translational medicine · (2026) · View on PubMed ↗
Influenza Activity and Estimated Vaccine Effectiveness During the 2025-2026 Influenza Season.
This surveillance study characterized influenza activity and estimated vaccine effectiveness during the 2025–2026 Northern Hemisphere season, focusing on antigenically drifted influenza A(H3N2) J.2.4.1 (subclade K) viruses. It used multi-source surveillance of influenza-positive respiratory specimens from ~300 clinical and ~100 public health laboratories and assessed antiviral susceptibility and postvaccination antibody responses to estimate vaccine effectiveness. The results inform public health expectations for vaccine performance and antiviral risk during a specific dominant H3N2 subclade.
Azziz-Baumgartner E, Budd A, Lee JS et al. · JAMA network open · (2026) · View on PubMed ↗ · Free PDF ↗
Budget Impact of Strategies Involving RSVpreF and Nirsevimab to Protect Infants in Saudi Arabia Against Respiratory Syncytial Virus.
This deterministic cohort budget impact model estimated the clinical and economic effects of maternal RSVpreF vaccination and single-dose nirsevimab to prevent RSV lower respiratory tract illness in infants in Saudi Arabia across five annual birth cohorts. The key finding was the projected budget impact of implementing RSVpreF and/or nirsevimab strategies compared with no intervention, using Saudi Arabia–specific inputs where available. These results are important for health policy planning by informing cost-effectiveness and affordability of RSV prevention programs for infants in KSA.
Alharbi AS, Abu-Shraie N, Al Abdulkarim H et al. · Infectious diseases and therapy · (2026) · View on PubMed ↗ · Free PDF ↗
Autoimmune & Inflammatory Disease (Clinical Trials/Comparative)
Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study.
This nationwide Swedish cohort study compared infection risk between anti-CD20 therapies—ocrelizumab and rituximab—in 16,872 multiple sclerosis (MS) treatment episodes from 2014–2025. It found that both rituximab and ocrelizumab had higher infection rates than other DMTs, while relapse rates were substantially lower with these therapies. The results are clinically significant for balancing efficacy versus infectious risk when choosing and monitoring anti-CD20 treatment in MS.
Frisell T, Hedberg S, Piehl F · Annals of neurology · (2026) · View on PubMed ↗
Compensatory relationships determine the impact of TGF-β on the humoral immune response to hepatitis B surface antigen.
This immunology study analyzed how compensatory relationships shape the effect of TGF-β on the humoral immune response to hepatitis B surface antigen (HBsAg), relevant to HBV seroconversion and chronic infection risk. The authors found that TGF-β’s impact on HBsAg-specific antibody responses depends on interacting regulatory pathways (including IL-10/Tregs-related mechanisms), rather than acting in isolation. The work improves understanding of early immune regulation underlying HBV seroconversion, informing strategies aimed at achieving functional cure.
Cimino JL, Moshkani S, Bailey JT et al. · Journal of immunology (Baltimore, Md. : 1950) · (2026) · View on PubMed ↗
Phase Ib, multicentre, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered mosunetuzumab in participants with systemic lupus erythematosus.
This phase Ib, multicentre, open-label dose-escalation study evaluated subcutaneous mosunetuzumab (a CD20xCD3 T-cell-engaging bispecific antibody) for safety, tolerability, pharmacokinetics, and pharmacodynamics in 15 participants with active autoantibody-positive systemic lupus erythematosus (SLE). The study’s core finding (from the reported design and early results) is that mosunetuzumab dosing via fixed and step-up cohorts was assessed for tolerability and immune/PK/PD activity in this SLE population. These data support the feasibility of subcutaneous mosunetuzumab development in SLE and inform dosing for subsequent trials.
Martins E, Chindalore VL, Sheng XR et al. · Lupus science & medicine · (2026) · View on PubMed ↗
Histologic and combined histologic-endoscopic outcomes with mirikizumab in Crohn’s disease: VIVID-1 trial results.
This analysis of the VIVID-1 trial compared histologic and combined histologic-endoscopic outcomes for mirikizumab versus placebo and ustekinumab in moderately-to-severely active Crohn’s disease. The key finding was that mirikizumab achieved histologic response and combined histologic-endoscopic improvements at weeks 12 and 52 based on segment-based Robarts Histopathology Index–derived criteria. This is significant because it positions microscopic inflammation endpoints as measurable targets for evaluating Crohn’s disease treatment efficacy.
Jairath V, Magro F, Protic M et al. · Journal of Crohn’s & colitis · (2026) · View on PubMed ↗
Bruton’s tyrosine kinase inhibitors: a new class of multiple sclerosis therapeutics.
This review summarized the development and rationale for Bruton’s tyrosine kinase inhibitors (BTKIs) as multiple sclerosis therapeutics, focusing on their immunomodulatory effects on B cells and microglia and their potential to cross the blood–brain barrier. The key finding was that multiple BTKIs are in evaluation for MS with pharmacologic differences that may influence efficacy and safety. Scientifically, it frames BTK inhibition as a promising CNS-relevant immune strategy for MS and guides interpretation of ongoing trials.
Oh J, Bar-Or A, Montalban X et al. · The Lancet. Neurology · (2026) · View on PubMed ↗
Efficacy and safety of belimumab and anifrolumab in systemic lupus erythematosus: A systematic review and network meta-analysis.
This systematic review and network meta-analysis compared belimumab versus anifrolumab for systemic lupus erythematosus (SLE) in adult patients using randomized controlled trials where each drug plus standard of care was compared with placebo plus standard of care. The key finding was a comparative synthesis of efficacy outcomes (including SRI-4 and BICLA, plus selected BILAG organ-domain responses) and safety endpoints using odds ratios with confidence intervals, with certainty assessed via GRADE/CINeMA (abstract truncated before the specific comparative results). Clinically, the analysis informs relative benefit–risk expectations between two biologics for SLE treatment selection.
Martinez-Martinez MU, Tejada-Llacsa PJ, Prokop LJ et al. · Seminars in arthritis and rheumatism · (2026) · View on PubMed ↗
Functional Profiling of Acetylcholine Receptor Antibodies Informs Therapeutic Outcome of FcRn Inhibitor Therapy in Myasthenia Gravis.
This work investigated how functional profiling of acetylcholine receptor (AChR) antibodies in myasthenia gravis (MG) relates to therapeutic outcomes during FcRn inhibitor therapy in patients with AChR-antibody–associated MG. It focuses on standardizing functional assays that distinguish pathogenic AChR-Ab mechanisms (including complement activation) to serve as markers of response to FcRn blockade. The findings are significant because they could enable more predictive, mechanism-informed selection and monitoring of FcRn inhibitor treatment in MG.
Morcone V, Morroni J, Valenzano G et al. · Neurology(R) neuroimmunology & neuroinflammation · (2026) · View on PubMed ↗
Systemic Proteomic Alterations and Predictive Biomarkers of Paroxetine Response in Refractory Rosacea: A Secondary Analysis of a Randomized Clinical Trial.
This secondary analysis used prospective plasma proteomics to investigate systemic proteomic alterations and identify predictive biomarkers of response to paroxetine in patients with refractory erythematous rosacea enrolled in a multicenter randomized, double-blind, placebo-controlled trial. The study found specific proteomic changes associated with paroxetine response and candidate biomarkers that could predict which patients benefit. This supports a move toward precision treatment in rosacea by linking systemic molecular signatures to therapeutic efficacy of paroxetine.
Wang B, Deng X, Zhang Y et al. · JAMA dermatology · (2026) · View on PubMed ↗
A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence.
This indirect comparative analysis used a novel Durability Index to estimate week-52 efficacy under variable treatment adherence for lebrikizumab, dupilumab, and tralokinumab monotherapy in moderate-to-severe atopic dermatitis. The key finding was that differences in estimated durability of response emerged across biologics when adherence to maintenance dosing varied. This is clinically relevant for real-world decision-making because it quantifies how treatment interruptions may affect long-term effectiveness of major anti–type 2 inflammation therapies.
Silverberg JI, Irvine AD, Foley P et al. · Dermatology and therapy · (2026) · View on PubMed ↗ · Free PDF ↗
Metabolic Disease & Obesity/Diabetes (Clinical/Comparative)
GLP-1 Receptor Agonists in Neurological Disorders: From Mechanisms to Clinical Translation.
This review evaluated evidence for repurposing glucagon-like peptide-1 receptor agonists (GLP-1RAs) across neurological disorders, focusing on CNS mechanisms and translational hurdles. It reports that preclinical neuroprotective effects are consistently linked to activation of the cAMP/PKA/CREB pathway and downstream neurotrophic signaling (e.g., BDNF), while clinical translation remains limited by unresolved issues such as target engagement and trial design. The work is significant because it frames GLP-1RAs as mechanistically plausible neuroprotective candidates and highlights the key barriers to testing them effectively in patients.
Li P, Gao Y, Liu W · Drug design, development and therapy · (2026) · View on PubMed ↗
Effects of different exercise interventions on body composition in women with overweight and obesity: a systematic review and network meta-analysis.
This systematic review and network meta-analysis evaluated which exercise interventions most improve body composition in adult women with overweight or obesity, using randomized controlled trials and CINeMA to compare confidence across a network. The key finding was that different structured exercise types showed differential effects on body composition outcomes, with relative effectiveness varying by intervention category. Clinically, it helps guide selection of exercise modalities for weight and body-composition improvement in women with overweight/obesity.
Song S, Wei Y, Zhang H et al. · BMJ open · (2026) · View on PubMed ↗
1-year outcomes of semaglutide, tirzepatide, and sleeve gastrectomy in obesity in type 2 diabetes: a retrospective cohort study.
This retrospective cohort study compared 1-year outcomes of semaglutide, tirzepatide, and sleeve gastrectomy in real-world adults with obesity and type 2 diabetes using the Epic Cosmos electronic health record dataset. The key finding was the relative differences in weight loss and glycaemic outcomes (and selected safety outcomes) among the three treatment strategies over 12 months. Clinically, it provides comparative effectiveness evidence to guide selection between GLP-1/GIP-based pharmacotherapy and bariatric surgery in type 2 diabetes with obesity.
Leslie DB, Steffen BT, Wise E et al. · The lancet. Diabetes & endocrinology · (2026) · View on PubMed ↗
Effects of Semaglutide on Body Composition and GFR: A Prespecified Analysis of the SMART Trial.
This prespecified analysis of the SMART trial assessed how semaglutide versus placebo affects body composition and estimated GFR in adults with chronic kidney disease (CKD) and overweight or obesity. Semaglutide reduced lean body mass and fat mass over 24 weeks, and changes in lean/fat mass did not correlate with changes in creatinine or cystatin C–eGFR or measured GFR. Scientifically and clinically, the findings suggest semaglutide’s effects on eGFR biomarkers are not driven by body composition changes, informing interpretation of kidney function during GLP-1 receptor agonist therapy.
Heerspink HJL, Soler M, Beernink JM et al. · Clinical journal of the American Society of Nephrology : CJASN · (2026) · View on PubMed ↗
Liver, Gastrointestinal & Gut Microbiome (Mechanisms/Trials)
Use of genetic analysis in adult cholestatic liver disease: lessons from progressive paediatric syndromes and cohort studies.
This review synthesized evidence on how genetic analysis informs adult cholestatic liver disease by drawing lessons from progressive pediatric cholestatic syndromes and cohort studies. It highlights that functional variants in PFIC-associated genes—especially ABCB4, ABCB11, and ATP8B1—underlie many genetic cholestasis phenotypes and can guide diagnosis beyond classic pediatric presentations. The clinical significance is improved genetic stratification of cholestatic disorders, enabling more precise prognostication and management.
Liebe R, Lammert F, Schmidt HH et al. · Gut · (2026) · View on PubMed ↗
Combined acetaldehyde metabolism burden modifies IBD susceptibility to alcohol consumption.
This prospective cohort study tested whether alcohol consumption’s association with inflammatory bowel disease (IBD) is modified by genetic capacity for acetaldehyde metabolism, using an acetaldehyde burden score derived from variants in alcohol dehydrogenase and aldehyde dehydrogenase. The key finding was that combined acetaldehyde metabolism burden altered susceptibility to IBD in relation to alcohol intake, supported by genetic and metabolomic analyses plus complementary mouse and human-derived experiments. This suggests that individual differences in acetaldehyde metabolism may explain inconsistent alcohol–IBD relationships and could inform risk stratification.
Chen J, Guo Y, Hu J et al. · Gut · (2026) · View on PubMed ↗
Impaired glycoRNA biogenesis in metabolic-dysfunction associated steatotic liver disease.
The study examined glycosylated non-coding small RNAs (glycoRNAs) and their biosynthesis mediators in metabolic-dysfunction associated steatotic liver disease (MASLD) using northern blot and an imaging approach combining a sialic acid aptamer with RNA in situ hybridization–mediated proximity ligation assay. It found impaired glycoRNA biogenesis in MASLD and used in vivo restoration of key glycoRNA biosynthesis mediators via adeno-associated viral (AAV) vectors to rescue this defect. These findings suggest glycoRNA biogenesis is mechanistically linked to MASLD pathology and could represent a therapeutic target.
Dong C, Zhong X, Peng Q et al. · Journal of hepatology · (2026) · View on PubMed ↗
Hepatocyte-to-intestinal stem cell remote communication regulates blood glucose homeostasis.
This mechanistic study investigated how fatty liver worsens hyperglycemia via remote hepatocyte-to-intestinal stem cell (ISC) communication, focusing on hepatocyte alkaline phosphatase (ALP) signaling to ISCs. The authors found that hepatocyte-derived ALP targets α2δ-1 in ISCs to promote Cav1.2 membrane translocation, increasing intracellular calcium and activating calcineurin/NFATC2 signaling to inhibit SOX21 expression, thereby impairing glucose homeostasis. These findings identify a liver–gut stem cell signaling axis (ALP–α2δ-1–Cav1.2–calcineurin/NFATC2–SOX21) as a potential therapeutic target for fatty-liver–associated hyperglycemia.
Ye J, Wan Q, Liu X et al. · Cell metabolism · (2026) · View on PubMed ↗
Adjunctive fecal microbiota transplantation for major depressive disorder: A randomized, double-blind, placebo-controlled trial.
This randomized, double-blind, placebo-controlled trial tested adjunctive fecal microbiota transplantation (FMT) capsules given for 2 weeks versus placebo in patients with major depressive disorder receiving escitalopram (ChiCTR2300071421). Although remission at week 8 did not differ significantly between groups, FMT produced greater reductions in HAM-D-17 scores at weeks 2 and 8 and was well-tolerated with a safety profile comparable to placebo. The results support targeted microbiome modulation as an adjunct strategy that may improve early-to-mid symptom trajectories in MDD.
Li J, Wang Y, Li R et al. · Cell host & microbe · (2026) · View on PubMed ↗
Reproductive Health, Fertility & Aging
Maternal trans-vaccenic acid shapes neonatal T cell development and early-life immune imprinting.
The study investigated whether maternal supplementation with trans-vaccenic acid (TVA), a trans-fatty acid abundant in human breast milk, shapes neonatal T cell development and immune imprinting in mice. TVA feeding expanded naïve CD4+ T cells and enhanced adaptive infection immunity, reprogramming neonatal naïve CD4+ T cells via a G protein-coupled receptor–CCCTC-binding factor (GPR–CTCF) axis and promoting Th1 skewing through cooperation with the transcription factor TBX21. These findings suggest a specific maternal dietary lipid can program early-life T cell fate through defined receptor–transcriptional pathways, informing nutritional strategies to modulate neonatal immunity.
Fan H, Zheng Z, Oliphant K et al. · Science (New York, N.Y.) · (2026) · View on PubMed ↗
Letrozole and Infertility Among Males With Spermatogenic Failure: A Randomized Clinical Trial.
The randomized clinical trial evaluated letrozole versus placebo/standard care for improving sperm concentration categories in men with spermatogenic failure (nonobstructive azoospermia, cryptozoospermia, or severe oligozoospermia) across 10 male infertility centers in China. The study tested efficacy and safety using an open-label, assessor-blinded design to determine whether aromatase inhibition improves spermatogenic recovery. This provides higher-quality evidence for using letrozole as a medical treatment option in male infertility due to spermatogenic failure.
Sun Y, Yao C, Liu G et al. · JAMA network open · (2026) · View on PubMed ↗
Aging disrupts spatiotemporal coordination in the cycling murine ovary.
This study used Slide-seq spatial transcriptomics to profile 22 murine ovaries across the reproductive cycle and chronological aging, capturing 610,620 spatial spots to analyze multicellular dynamics. It found that aging disrupts spatiotemporal coordination among oocytes, follicles, and corpora lutea, impairing the coordination required for folliculogenesis. These results identify where and when ovarian aging derails tissue-level developmental programs, informing strategies to preserve fertility with age.
Lan TCT, Kochersberger A, Raichur R et al. · Nature aging · (2026) · View on PubMed ↗
NEDDylation maintains oocyte quality by stabilizing mitochondrial transcription.
This study examined whether oocyte-specific NEDDylation, via deletion of Uba3 (catalytic subunit of the E1 NEDDylation-activating complex), preserves mitochondrial function and oocyte quality in mice. Uba3 conditional knockout oocytes showed mitochondrial dysfunction with increased reactive oxygen species, impaired oxidative phosphorylation, and depletion of mitochondrially encoded RNA transcripts, indicating disrupted mitochondrial transcriptional maintenance. These findings identify Uba3-dependent NEDDylation as a mechanistic regulator of mitochondrial transcription and a potential target for preventing age-related female infertility.
Ahmed AA, Steenwinkel TE, Patton BK et al. · Science advances · (2026) · View on PubMed ↗
Aging, Senescence & Longevity Interventions
Profiling the molecular and physiological effects of senolytic treatment on aged mice identifies immune, fibrotic and metabolic remodeling.
This study assessed the molecular and physiological effects of senolytic treatment with dasatinib plus quercetin (D+Q) in aged mice using unbiased multitissue single-cell analysis, integrative transcriptomics, histopathology, and molecular profiling. It found that D+Q remodels aging-associated phenotypes, particularly by altering immune, fibrotic, and metabolic states across tissues. The significance is improved understanding of tissue-specific senolytic impact and potential optimization of timing and targeting to maximize benefits while minimizing off-target effects.
Hou J, Chen KX, Xiao QN et al. · Nature aging · (2026) · View on PubMed ↗
Molecular & Cellular Mechanisms (Genomics, Epigenetics, RNA, Cell Death, Metabolism)
Analysis of 173,303 exomes and genomes in the Pakistan Genome Resource.
This population genomics study analyzed 173,303 exomes and genomes in the Pakistan Genome Resource biobank to characterize naturally occurring homozygous loss-of-function variants. The key finding was that participants collectively carry homozygous loss-of-function variants in 6,476 genes, enabling systematic discovery of rare gene targets that mimic pharmacological inhibition. This is significant for accelerating drug target discovery and improving representation of South Asian genetic diversity in precision medicine research.
Koch C, Khalid S, Khan MZ et al. · Nature · (2026) · View on PubMed ↗
Spatial distribution of the proteome in the human body and in cancers.
This study generated a spatially resolved proteomic atlas by profiling more than 13,000 proteins across 2,856 samples using data-independent acquisition (DIA) mass spectrometry. The key finding was a comprehensive map covering 58 tissue types, 251 tissue subtypes, and 25 carcinomas, enabling visualization of proteome trajectories across fetal, tumor, adjacent non-tumor, and healthy adult states. The significance is that it provides a high-resolution resource to study tissue-specific biology and cancer progression mechanisms using spatial proteomics.
Yue L, Jiang W, Li S et al. · Nature · (2026) · View on PubMed ↗
Structure of the pre-initiation complex explains CMGE biogenesis.
This study reconstituted the yeast CMG (Cdc45–MCM–GINS–Pol ε) DNA replication helicase pre-initiation complex using purified firing factors to determine how CMGE biogenesis proceeds. Cryo-electron microscopy captured stepwise assembly of two symmetrical CMGEs and showed how complex formation reshapes MCM to prepare for DNA opening and fork establishment. These structural insights clarify the mechanistic choreography of S-phase origin firing and provide a blueprint for understanding replication initiation defects in genome instability diseases.
Pühringer T, Canal B, Palm G et al. · Nature · (2026) · View on PubMed ↗
Towards autonomous medical artificial intelligence agents.
This work developed and tested MIRA (Medical Intelligence for Reasoning and Action), an autonomous AI agent operating in a sandboxed electronic health record (EHR) environment with governed access and permitted actions. The key finding is that MIRA can manage patient cases with physician-level performance while staying within defined safety constraints for EHR interactions. This supports the feasibility of integrating autonomous clinical decision-and-action systems into real-world workflows rather than limiting LLMs to narrow chat interfaces.
Ferber D, Hilgers L, Höper C et al. · Nature · (2026) · View on PubMed ↗
Cortical development dynamics across autism spectrum disorder mouse models.
This study profiled 251 samples from 11 monogenic autism spectrum disorder (ASD) mouse models using single-nucleus multi-omic sequencing across developmental stages, sexes, and two brain regions to identify convergent pathways. Despite genetic heterogeneity, ASD-linked mutations converged on perturbations of the radial glial cell lineage consistent with a transient developmental delay that resolves by postnatal stages. These findings point to radial glial lineage timing as a shared neurodevelopmental mechanism across diverse ASD genes and suggest a window for targeted interventions.
Schwarz LA, Dotter CP, Isaev S et al. · Nature · (2026) · View on PubMed ↗
Confined migration induces non-lethal DNA damage in developing neurons.
This study examined developing mouse cerebral and cerebellar neurons during migration through narrow interstitial spaces to determine whether physiological mechanostress causes DNA damage. It found massive DNA double-strand breaks (DSBs) during confined migration without detectable nuclear envelope rupture. The results establish that non-lethal DNA damage can be a normal consequence of neuronal migration mechanics, informing how genome integrity is protected during brain development.
Zhang Z, Canela A, Kurisu J et al. · Nature · (2026) · View on PubMed ↗
Molecular basis of polyadenylated RNA fate determination in the nucleus.
This study investigated how polyadenylated RNAs are sorted in the nucleus for functional export versus degradation, focusing on the DExD-box ATPase UAP56/DDX39B and the poly(A) tail exosome targeting (PAXT) pathway. It revealed molecular determinants that connect poly(A) tail status to exosome targeting and thereby determine whether pA+ RNPs are released for export or degraded in the nucleus. These mechanistic insights clarify a core gene-expression quality-control step and identify potential targets for disorders involving RNA processing and export.
Bugai A, Hohmann U, Lorenzo A et al. · Nature · (2026) · View on PubMed ↗
15-LOX-catalytic bias towards ether-(alkenyl)-ETE-PEs oxidation bestows selectivity of PRO-ferroptotic cell death signaling.
Using redox lipidomics, biochemical/biophysical assays, genetic approaches, and molecular dynamics simulations, this study investigated how 15-LOX preferentially oxidizes ether-(alkenyl)-ETE-PEs to generate pro-ferroptotic signaling. The authors found that 15-LOX catalytic bias toward specific ether-(alkenyl)-ETE-PE oxidation produces selective ferroptosis-promoting lipid signals (15-HpETE-PEs). This mechanistic specificity clarifies how 15-LOX controls ferroptotic versus anti-ferroptotic lipid pathways and may guide targeted ferroptosis modulation.
Tyurina YY, Mikulska-Ruminska K, Tyurin VA et al. · Nature communications · (2026) · View on PubMed ↗
Intermediate accumulated upon interruption of fatty acid oxidation flux promotes tumoral ferroptosis and improves immunotherapy.
This study tested whether interrupting fatty acid oxidation (FAO) at specific nodes promotes ferroptosis and improves antitumor immunotherapy, focusing on the HADHA step and hydroxylated C18 (C18-OH) acylcarnitine accumulation. In vivo and mechanistic experiments showed that HADHA inhibition or HADHA ablation increased tumoral ferroptosis and enhanced immunotherapy responses, whereas upstream FAO targeting did not. The results identify HADHA as a metabolic control point that can be exploited to potentiate ferroptosis-driven cancer immunity.
Zhou Y, Li J, Liu F et al. · Nature communications · (2026) · View on PubMed ↗
Targeting N1-methyladenosine modification in osteoblasts through tRNA methyltransferase 10C reverses mitochondrial dysfunction and ameliorates osteoporosis.
In osteoblasts from osteoporosis mouse models, this study examined the role of the nuclear-encoded tRNA methyltransferase TRMT10C (Trmt10c) in mitochondrial oxidative phosphorylation dysfunction and tested whether targeting N1-methyladenosine (m1A) could reverse defects. TRMT10C expression and OXPHOS subunits were reduced in osteoblasts, and conditional Trmt10c knockout in osterix-expressing progenitors worsened growth and bone phenotypes, while restoring m1A-related function improved mitochondrial performance. These data suggest that correcting TRMT10C-dependent m1A modification can ameliorate mitochondrial dysfunction and osteoporosis.
Sun H, Wang W, Zhang C et al. · Signal transduction and targeted therapy · (2026) · View on PubMed ↗
iSCORE-PD: an isogenic stem cell collection to research Parkinson’s disease.
The iSCORE-PD study created an isogenic collection of 65 genome-edited human pluripotent stem cell lines carrying disease-causing or high-risk variants in 11 Parkinson’s disease genes (SNCA, PRKN, PINK1, DJ1/PARK7, LRRK2, ATP13A2, FBXO7, DNAJC6, SYNJ1, VPS13C, and GBA1). Whole-genome sequencing and quality control showed that genetic variation between lines is largely limited (mostly non-coding) compared with differences seen across patient-derived hiPSCs. This resource enables controlled, gene-specific modeling of PD mechanisms and accelerates systematic testing of disease-relevant phenotypes across defined genetic backgrounds.
Busquets O, Li H, Syed KM et al. · Nature communications · (2026) · View on PubMed ↗
Guide RNA reprogramming facilitates minimized tracrRNA-dependent off-target and versatile CRISPR/Cas9 engineering.
This study investigated CRISPR/Cas9 guide RNA (gRNA) design by analyzing how the crRNA:tracrRNA duplex can be split and reprogrammed, and how this affects tracrRNA-dependent off-target (TDO) effects in human/mouse contexts. The authors found that endogenous RNAs with crRNA-like sequences can hijack reprogrammable gRNAs to drive low-frequency but pervasive TDO, and they used machine learning on high-throughput gRNA variant screens to derive design rules and engineer crRNA variants mismatched to human/mouse transcriptomes to minimize TDO. The work provides a safer, more versatile CRISPR/Cas9 engineering strategy by reducing tracrRNA-dependent off-target activity.
Yu W, Chen J, Guo J et al. · Nature communications · (2026) · View on PubMed ↗
Reverse engineering of BNIP3 identifies a mitochondrial protective peptide.
This study reverse-engineered the mitochondrial BH3-only protein BNIP3 using structural modeling and sequence-function analyses to identify domains and amino-acid hotspots that activate BCL-2 family executioner proteins. Based on these insights, the authors developed a BNIP3 antagonist peptide (B-017) that disrupts BNIP3–BCL-2 executioner interactions and thereby protects mitochondria from cell death. This provides a rational, target-specific mitochondrial protective peptide strategy for diseases where BNIP3-driven mitochondrial apoptosis is pathogenic.
Hendgen-Cotta UB, Roth A, Beuck C et al. · Nature communications · (2026) · View on PubMed ↗
Comparing the Effect of Scaling and Polishing on Nine Oral Health and Dental Aesthetic Measures between Current and Never Smokers from the SMILE Study Cohort.
This study compared the short-term effects of professional scaling and polishing on oral health and dental aesthetic measures between current and never smokers in the SMILE cohort. After 14 days, scaling and polishing produced measurable changes across multiple outcomes (including gingival indices and quantitative light-induced fluorescence plaque/calculus measures), with differences assessed by smoking status. The findings are clinically relevant for tailoring preventive dental care and interpreting treatment response in smokers versus never smokers.
La Rosa GRM, Kowalski J, Isola G et al. · Journal of dentistry · (2026) · View on PubMed ↗
Relationships between cannabis use and mental disorders: assessing the coherence of evidence from studies with different methodologies.
This evidence-coherence assessment synthesized findings across epidemiological, genetic, experimental, and preclinical studies to evaluate relationships between daily cannabis use and mental disorders (including psychosis, bipolar disorder, anxiety, depression, and suicidal behaviours). The key finding was credible evidence that daily cannabis use is a contributory cause of psychosis. This supports causal inference in public health and clinical guidance regarding cannabis exposure and psychosis risk.
Hall W, Yimer TM, Thorne RL et al. · The lancet. Psychiatry · (2026) · View on PubMed ↗
Complete chromosome 21 centromere sequencing of families with Down syndrome.
This study used long-read sequencing to fully sequence and assemble chromosome 21 centromeres from eight families with a child with Down syndrome (trisomy 21), including one parent–child trio, six mother–child duos, and one singleton. The key finding was successful complete centromere sequencing despite repetitive and homologous regions with chromosome 13, with all cases arising from maternal meiosis I errors. Scientifically, this enables more precise investigation of centromere size/sequence features in nondisjunction mechanisms underlying trisomy 21.
Mastrorosa FK, Daponte A, de Gennaro L et al. · American journal of human genetics · (2026) · View on PubMed ↗
Chloroplast sunscreening by protein condensates confers high-light tolerance.
This research examined how chloroplast protein condensates mediate high-light tolerance by sensing singlet oxygen (¹O₂), focusing on the conserved ¹O₂-response mediator METHYLENE BLUE SENSITIVITY1 (MBS1). The authors found that MBS1 undergoes Zn-finger (ZnF) conformational change and phase transition from liquid-like droplets to lower-dynamic condensates, and that these chloroplast-associated condensates attenuate photodamage under high light. The work identifies a rapid, condensate-based ¹O₂ sensing mechanism that could inform strategies to enhance photosynthetic stress tolerance.
Shao N, Chen M, Xu N et al. · Cell · (2026) · View on PubMed ↗
Life-span-dependent transcriptional dynamics of the human heart.
This study used single-nucleus RNA sequencing to map lifespan-dependent transcriptional dynamics across 54 nonfailing human myocardial tissue samples from 29 individuals spanning development, adulthood, and aging. It found coordinated but cell type-specific transcriptional trajectories across major cardiac cell types, converging on progressive loss of gene expression homeostasis, stress responses, and inflammatory signaling with age. The resulting atlas clarifies regulatory programs that shift over the human lifespan and may inform interventions to preserve cardiac function during aging.
Jia H, Chen X, Chang Y et al. · Science advances · (2026) · View on PubMed ↗
Aptamer-functionalized apoptotic vesicles ameliorate osteoarthritis via resuming mitochondria OXPHOS of chondrocytes.
This study tested whether aptamer-functionalized apoptotic vesicles (tgg2@apoVs), using the chondrocyte-binding aptamer tgg2, can treat osteoarthritis by restoring mitochondrial oxidative phosphorylation (OXPHOS) in chondrocytes. The key finding was that tgg2@apoVs improved osteoarthritis outcomes by resuming chondrocyte mitochondrial OXPHOS, addressing mitochondrial impairment linked to cartilage matrix dysregulation. This supports a targeted vesicle-delivery strategy to overcome poor chondrocyte targeting and short joint retention that has limited prior apoptotic vesicle therapies.
Wang Z, Jiang Y, Xu X et al. · Science advances · (2026) · View on PubMed ↗
ENO1 couples HDAC1 to regulate histone lactylation and gene transcription.
This study identified how ENO1 (enolase-1) regulates histone lactylation and gene transcription by coupling to HDAC1 in living cells. Using BimPL, a heterobifunctional proximity labeling technique with quantitative proteomics, the authors found that ENO1 translocates to the nucleus and interacts with HDAC1 at chromatin to control histone lactylation-dependent transcription. This mechanistic link connects glycolysis-associated ENO1 to epigenetic regulation, highlighting a pathway that could be targeted in diseases with altered lactylation or HDAC activity.
Zhai G, Zhao F, Wang Y et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗
Generated automatically on June 19, 2026 from PubMed’s trending articles. Summaries are AI-generated; always consult the original publication for clinical or research decisions.